On Sunday, 
FierceBiotech's Damian Garde (@DamianFierce) and ISI analyst Mark Schoenebaum (@MarkSchoenebaum) discussed a promising crop of new cancer-fighting immunotherapies under the spotlight at the weekend's American Society of Clinical Oncology conference. Their discussion, the second of a three-part Twitter conversation, touches on in-development drugs from Bristol-Myers Squibb ($BMY), Merck ($MRK), Roche ($RHHBY) and AstraZeneca ($AZN).
Find more info on the chat series here. These chats are sponsored by Covance.